Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Biomea Fusion, Inc. before investing.

In this article, we go over a few key elements for understanding Biomea Fusion, Inc.’s stock price such as:

• Biomea Fusion, Inc.’s current stock price and volume
• Why Biomea Fusion, Inc.’s stock price changed recently
• Upgrades and downgrades for BMEA from analysts
• BMEA’s stock price momentum as measured by its relative strength

About Biomea Fusion, Inc. (BMEA)

Before we jump into Biomea Fusion, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Want to learn more about Biomea Fusion, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Biomea Fusion, Inc..

Biomea Fusion, Inc.’s Stock Price as of Market Close

As of May 07, 2026, 10:15 AM, CST, Biomea Fusion, Inc.’s stock price was $1.600.

Biomea Fusion, Inc. is 0% from its previous closing price of $1.600.

During the last market session, Biomea Fusion, Inc.’s stock traded between $1.550 and $1.610. Currently, there are approximately 71.55 million shares outstanding for Biomea Fusion, Inc..

Biomea Fusion, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Biomea Fusion, Inc. Stock Price History

Biomea Fusion, Inc.’s (BMEA) price is currently up 17.65% so far this month.

During the month of May, Biomea Fusion, Inc.’s stock price has reached a high of $1.730 and a low of $1.280.

Over the last year, Biomea Fusion, Inc. has hit prices as high as $3.080 and as low as $0.872. Year to date, Biomea Fusion, Inc.’s stock is up 29.03%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Biomea Fusion, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 06, 2026, there were 0 analysts who downgraded Biomea Fusion, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Biomea Fusion, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Biomea Fusion, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Biomea Fusion, Inc. (BMEA) by visiting AAII Stock Evaluator.

Relative Price Strength of Biomea Fusion, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 06, 2026, Biomea Fusion, Inc. has a weighted four-quarter relative price strength of 1.52%, which translates to a Momentum Score of 63 and is considered to be Strong.

Want to learn more about how Biomea Fusion, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Biomea Fusion, Inc. Stock Price: Bottom Line

As of May 7, 2026, Biomea Fusion, Inc.’s stock price is $1.600, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Biomea Fusion, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.